Equities

Essex Bio-Technology Ltd

Essex Bio-Technology Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.39
  • Today's Change0.04 / 1.70%
  • Shares traded100.00k
  • 1 Year change-27.58%
  • Beta0.5888
Data delayed at least 15 minutes, as of Jul 26 2024 08:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.

  • Revenue in HKD (TTM)1.71bn
  • Net income in HKD275.26m
  • Incorporated2000
  • Employees1.48k
  • Location
    Essex Bio-Technology LtdRoom 2818,Chn Mrchnts Twr,Shn Tk Ctr168-200 Connaught Road CentralCentral Hong KongHKG
  • Phone+852 25877838
  • Fax+852 25877363
  • Websitehttp://www.essexbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd908.51m160.00m722.72m848.004.520.45225.900.79550.28560.28561.622.850.35872.182.941,071,356.006.327.679.1210.4869.4078.7917.6120.681.51--0.05157.22-0.00495.38-23.43-1.67-1.14--
Pak Fah Yeow International Ltd259.16m105.04m732.35m102.006.970.95716.512.830.3370.3370.83162.460.29952.8822.182,540,765.0012.143.9912.604.1884.4580.7940.5321.276.9010.080.0062100.6876.0612.94250.6623.0218.83-8.06
Zhaoke Ophthalmology Ltd20.24m-415.68m737.29m313.00--0.3334--36.42-0.7642-0.76420.03724.050.0075--0.53164,670.97-15.43---17.27--75.98---2,053.54--5.32-47.540.1041------5.47------
Fusen Pharmaceutical Co Ltd610.62m-39.16m757.46m1.15k--1.25--1.24-0.0525-0.05250.81190.81120.41991.958.36531,895.30-2.690.9678-5.541.7452.9551.95-6.422.590.60960.7560.379727.9515.024.13-4.83--0.2124--
Jbm (Healthcare) Ltd648.42m130.46m808.80m279.006.560.83074.401.250.14790.14790.73381.170.46454.255.982,324,068.009.834.3812.045.5252.1446.4721.1612.691.2589.680.115532.9824.6216.09128.5119.992.26--
Hbm Holdings Ltd698.69m177.96m991.85m177.005.331.014.641.420.24210.24210.9521.280.38863.903.013,947,392.009.88-54.6114.13-66.0497.7397.8125.43-400.283.286.980.3556--120.13127.06116.61---12.62--
Zhongzhi Pharmaceutical Holdings Ltd2.21bn175.73m1.05bn2.64k5.880.93083.660.47610.20750.20752.611.311.122.5310.54837,277.308.957.6914.1511.7559.7360.448.016.730.894--0.142442.4612.2612.4153.0013.8617.653.22
VIVA Biotech Holdings2.33bn-125.35m1.08bn2.08k--0.2698.980.4644-0.0638-0.06381.201.860.28054.845.211,120,417.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.151.000.3412---9.4259.3178.03--31.98--
Jacobson Pharma Corporation Ltd1.47bn210.24m1.18bn1.72k5.390.49253.350.8040.10950.13910.76441.200.33112.476.37851,885.104.744.305.765.5742.2741.2514.3213.731.735.330.238240.6215.79-0.14011.31-3.0524.064.10
Ascletis Pharma Inc61.10m-156.23m1.20bn219.00--0.4908--19.64-0.1468-0.14680.05692.420.0222.303.86278,993.50-5.62-6.43-5.91-6.6445.9235.67-255.70-243.3816.54-6.090.0036--4.63-19.3954.04---20.44--
Essex Bio-Technology Ltd1.71bn275.26m1.36bn1.48k5.100.70514.050.79480.46890.46892.873.390.61612.283.351,152,300.009.9411.2013.2114.7390.2086.0116.1319.771.46--0.132616.1629.517.7222.113.567.297.39
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn351.94m1.73bn1.14k4.910.55983.821.390.23410.23410.82712.050.31562.316.371,087,267.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
SinoMab Bioscience Ltd1.47m-262.46m1.75bn215.00--5.19--1,185.39-0.2578-0.25780.00150.30830.0015----6,854.04-26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---11.480.604------14.45--106.81--
Cryofocus Medtech Shanghai Co Ltd44.21m-105.24m1.90bn392.00--10.89--42.94-0.4401-0.44010.18490.729------112,776.90--------75.83---258.23--4.08--0.0597--50.83--13.13------
Data as of Jul 26 2024. Currency figures normalised to Essex Bio-Technology Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

3.62%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Apr 202412.24m2.16%
Pheim Asset Management Sdn. Bhd.as of 31 Dec 20233.66m0.65%
Dimensional Fund Advisors LPas of 04 Jul 20243.62m0.64%
CATAM Asset Management AGas of 31 Mar 2021300.00k0.05%
Strategic Advisers LLCas of 31 May 2024193.00k0.03%
Dimensional Fund Advisors Ltd.as of 31 May 2024183.10k0.03%
American Century Investment Management, Inc.as of 03 Jul 2024141.00k0.03%
DFA Australia Ltd.as of 31 May 202476.67k0.01%
AXA Investment Managers UK Ltd.as of 31 May 202468.00k0.01%
EntrepreneurShares LLCas of 31 Mar 202447.32k0.01%
More ▼
Data from 31 Dec 2023 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.